(Reuters) -The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain by facilitating construction of manufacturing sites.

The program, called FDA PreCheck, aims to streamline review of domestic pharmaceutical manufacturing and eliminate unnecessary regulatory requirements, the FDA said.

The program also introduces a two-phase approach to facilitate new U.S. drug manufacturing facilities.

The initial phase would provide for more frequent communication with the FDA, including for facility design, construction and pre-production.

The second phase would facilitate pre-application meetings and early feedback to help streamline the development of manufacturing and quality control processes, the agency said.

“The FDA PreC

See Full Page